← Back to bills and search results
2025 · Regular session · House bill
HB3057
HB3057 sets a provider-access rule for covered health plans that already cover chimeric antigen receptor T-cell therapy, usually called CAR T-cell therapy.
Official caption: Relating to health benefit plan coverage for chimeric antigen receptor T-cell therapy.
Official report lists House author(s): Landgraf. This does not identify sponsors or amendment drafters.
Bill explanation published · Version and amendment review scope is stated below · Individual amendment records may not be separately annotated.
Bill highlights
Selected points from the published explanation. Follow each point to its source-linked context; conditions and limits may matter.
- HB3057 sets a provider-access rule for covered health plans that already cover chimeric antigen receptor T-cell therapy, usually called CAR T-cell therapy.
- The “any other service” wording matters: a qualifying provider need not already be in the plan's network specifically for CAR T-cell therapy.
- The act lists the covered insurers and plan categories, including individual and group insurance, HMOs, small-employer and standard health plans, specified state, school and university employee plans, and self-funded plans sponsored by professional employer organizations.
- The law took effect September 1, 2025, and applies only to plans delivered, issued for delivery or renewed on or after January 1, 2026.
- Federal qualification context: On June 26, 2025, the FDA removed the special risk-management programs for six listed CAR T-cell products, including their special facility-certification requirement.
What does it do?
HB3057 sets a provider-access rule for covered health plans that already cover chimeric antigen receptor T-cell therapy, usually called CAR T-cell therapy. It does not require every health plan to add that treatment as a new benefit. A covered plan must cover the therapy when it is medically necessary and administered by a provider meeting both statutory conditions: qualification as a certified facility under the procedure for the FDA-approved product license, and participation in the plan’s network for any other service. Final law, section 1.
The “any other service” wording matters: a qualifying provider need not already be in the plan’s network specifically for CAR T-cell therapy. But this is not a blanket entitlement to treatment at every out-of-network facility, and the act does not eliminate all deductibles, copayments or medical-necessity review.
The act lists the covered insurers and plan categories, including individual and group insurance, HMOs, small-employer and standard health plans, specified state, school and university employee plans, and self-funded plans sponsored by professional employer organizations. Medicaid, including managed care, and the Children’s Health Insurance Program are expressly excluded. The list should not be read as a claim that every self-funded employer plan is subject to this Texas law.
The law took effect September 1, 2025, and applies only to plans delivered, issued for delivery or renewed on or after January 1, 2026. The insurance commissioner must adopt rules as necessary. The governor signed June 20, 2025. Official history.
Federal qualification context: On June 26, 2025, the FDA removed the special risk-management programs for six listed CAR T-cell products, including their special facility-certification requirement. That later federal action should not be confused with HB3057’s final product-license wording. This briefing does not determine whether a particular facility satisfies that wording or whether a specific treatment is medically appropriate; those questions require current product requirements and plan/provider review.
What changed along the way?
The filed bill would have prohibited plans covering CAR T-cell therapy from refusing to contract with qualifying facilities or denying their administration of the therapy. The House committee substitute replaced that broad contracting language with a conditional coverage rule, added medical necessity and network participation, and expressly excluded Medicaid and CHIP.
Landgraf’s adopted House amendment replaced the substitute’s explicit enrollment-in-a-federal-risk-management-program language with qualification under the FDA-approved product-license procedure. It also added “with respect to any other service” to the network condition. Both changes survived into the final law. The amendment index lists this one amendment; the House-passed, Senate and final versions have the same substance. Text versions.
For the full amendment record, open the official amendment index.
Official bill versions
Compare the published text versions in the official text index. A change is not attributed to a specific amendment here without a verified record.
Who could benefit—and who could bear the costs?
Patients whose plans already cover CAR T-cell therapy may gain access to qualifying providers already in their network for another service. Those providers may gain patients; plans may need to adjust coverage administration. The law does not establish a treatment price, guarantee a clinical outcome or establish that every patient will qualify.
The May 20 fiscal note, for the text that became law, anticipates no significant state fiscal impact, assuming costs can be absorbed using existing resources, and no local-government fiscal impact. The earlier filed-version note estimated multimillion-dollar costs for school-employee health programs under the broader proposal. Those earlier estimates should not be presented as the final bill’s fiscal estimate. HB3057 makes no appropriation, and the final note does not quantify patients’ out-of-pocket savings or premium changes.
Official sources
- Bill history and latest recorded action
- Bill versions, analyses and fiscal notes
- Action history and votes
- Amendment index
Catalog report retrieved 2026-10-25. Check the official record for corrections or later changes.
